News articles about Versartis (NASDAQ:VSAR) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Versartis earned a news impact score of 0.10 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.0831486613309 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of Versartis (VSAR) remained flat at $$2.03 during trading on Tuesday. The company had a trading volume of 906,910 shares, compared to its average volume of 814,075. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 0.11. Versartis has a 52-week low of $1.60 and a 52-week high of $24.00.
Versartis (NASDAQ:VSAR) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.78). During the same period in the previous year, the company posted ($0.92) EPS. research analysts forecast that Versartis will post -4.14 EPS for the current fiscal year.
Several equities research analysts have commented on the stock. Piper Jaffray Companies downgraded shares of Versartis from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $26.00 to $4.00 in a report on Friday, September 22nd. ValuEngine downgraded shares of Versartis from a “hold” rating to a “sell” rating in a report on Thursday, August 17th. Barclays downgraded shares of Versartis from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $28.00 to $4.00 in a report on Friday, September 22nd. Citigroup downgraded shares of Versartis from a “buy” rating to a “neutral” rating and lowered their target price for the company from $23.00 to $3.00 in a research note on Monday, September 25th. Finally, SunTrust Banks downgraded shares of Versartis from a “buy” rating to a “hold” rating and lowered their target price for the company from $25.00 to $4.00 in a research note on Friday, September 22nd. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $7.22.
In related news, major shareholder Life Sciences Maste Perceptive sold 2,130,000 shares of Versartis stock in a transaction on Friday, September 22nd. The shares were sold at an average price of $3.29, for a total value of $7,007,700.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last quarter, insiders sold 2,132,769 shares of company stock worth $7,014,761. 10.90% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: This story was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/05/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-versartis-vsar-share-price.html.
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.